ReviewThe Journal of clinical endocrinology and metabolism2025
Approach to the Patient With Turner Syndrome.
Review in The Journal of clinical endocrinology and metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Sry-modified laboratory rat lines to study sex-chromosome effects underlying sex differences in physiology and disease: Four Core Genotypes and more.Biology of sex differences · 2026Article
- Impact of Clinical Factors on Bone Microarchitecture in Patients with Turner Syndrome.Endocrine, metabolic & immune disorders drug targets · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Turner syndrome is diagnosed in a female individual with partial or complete loss of the second sex chromosome and is reported in 1 in 2000 to 1 in 2500 live births. Common features include short stature and ovarian dysgenesis; subsequent ovarian insufficiency leading to delayed/absent puberty and infertility in the majority. It is associated with increased morbidity and mortality, due to comorbidities occurring throughout the lifespan, including congenital and acquired cardiovascular abnormalities, autoimmune disease, osteoporosis and other skeletal abnormalities, and metabolic dysfunction as well as neurocognitive challenges. Management may involve coordination of several specialties in addition to patient/relative information and support. Treatment with growth hormone during childhood and adolescence and sex hormone replacement therapy forms the cornerstone of medical treatment. Recent review of evidence and development of recommendations inform a practical approach to management with an aim to reduce morbidity and thus improve outcomes in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.